GRCE Grace Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: GRCE

Price (delayed)

$2.33

Market cap

$37.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.47

Enterprise value

$20.94M

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 24
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 11
Highlights
The EPS has dropped by 52% since the previous quarter but it rose by 41% year-on-year
Grace Therapeutics's net income has decreased by 30% from the previous quarter but it has increased by 19% YoY
Grace Therapeutics's quick ratio has decreased by 46% QoQ and by 31% YoY
The company's equity fell by 4.1% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acastipharma.com
Peers: OPK ORGO

Key stats

What are the main financial stats of GRCE

GRCE stock price

How has the Grace Therapeutics stock price performed over time
Intraday
-0.85%
1 week
-5.67%
1 month
0%
1 year
-27.19%
YTD
-32.66%
QTD
2.64%

Financial performance

How have Grace Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.08M
Net income
-$7.79M
Gross margin
N/A
Net margin
N/A
GRCE's operating income is up by 34% year-on-year and by 3.9% since the previous quarter
Grace Therapeutics's net income has decreased by 30% from the previous quarter but it has increased by 19% YoY

Price vs fundamentals

How does GRCE's price correlate with its fundamentals

Growth

What is Grace Therapeutics's growth rate over time

Valuation

What is Grace Therapeutics stock price valuation
P/E
N/A
P/B
0.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 52% since the previous quarter but it rose by 41% year-on-year
The stock's P/B is 30% below its last 4 quarters average of 0.8 but 12% above its 5-year quarterly average of 0.5
The company's equity fell by 4.1% YoY

Efficiency

How efficient is Grace Therapeutics business performance
The ROA has contracted by 34% from the previous quarter but it has grown by 20% YoY
The ROE has contracted by 31% from the previous quarter but it has grown by 25% YoY

Dividends

What is GRCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRCE.

Financial health

How did Grace Therapeutics financials performed over time
The total liabilities has contracted by 49% YoY and by 23% from the previous quarter
The company's current ratio fell by 46% QoQ and by 31% YoY
The debt is 100% lower than the equity
The company's equity fell by 4.1% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.